Study of acamprosate in youth with fragile X syndrome versus placebo
The purpose of this study is to learn more about the effectiveness of acamprosate versus placebo as a drug treatment for interfering symptoms associated with fragile X syndrome, such as irritability, hyperactivity and social impairment. This study will also help determine the amount of medicine that will be used in future treatment for children with FXS. Nationwide, 48 patients will be recruited for this study. At Rush University Medical Center, we expect to recruit approximately 24 patients. The treatment will be assigned randomly.
You may be eligible to participate in this study if you:
- Are between the ages of 5-17 with a diagnosis of fragile X syndrome
- Are able to swallow a large-capsule medication
You will be excluded from this study if you:
- Are taking more than two psychotropic drugs
- Have an unstable seizure disorder or a recent change in anti-convulsant drug dosing
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.